Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 4-amino-5-chloro-n-(1-(3-methoxypropyl)-4-piperidinyl)-2,3-dihydro-1-benzofuran-7-carboxamide
2. Motegrity
3. Prucalopride
4. R 093877
5. R093877
6. Resolor
7. Resotran
8. Resotrans
1. 179474-85-2
2. Resolor
3. Prucalopride Succinat
4. Prucalopride (succinate)
5. R-108512
6. Butanedioic Acid 4-amino-5-chloro-2,3-dihydro-n-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide
7. Prucalopride Succinate [usan]
8. Prucalopride (as Succinate)
9. 4v2g75e1ck
10. 179474-85-2 (succinate)
11. 4-amino-5-chloro-n-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide Succinate
12. Butanedioic Acid, Compd. With 4-amino-5-chloro-2,3-dihydro-n-(1-(3-methoxypropyl)-4-piperidinyl)-7-benzofurancarboxamide (1:1)
13. Butanedioic Acid, Compd. With 4-amino-5-chloro-2,3-dihydro-n-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide (1:1)
14. Prucalopride Succinate (usan)
15. Resotran
16. 4-amino-5-chloro-n-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide;butanedioic Acid
17. Resolor (tn)
18. Unii-4v2g75e1ck
19. R-93877
20. Resolor Succinate
21. Motegrity (tn)
22. Prucalopridesuccinate
23. R 108512
24. Mls006011219
25. Schembl1230437
26. Chembl2105748
27. Dtxsid701027749
28. Hms3652b21
29. Hms3885j13
30. Bcp09320
31. Mfcd00948731
32. S4247
33. Akos015994741
34. Prucalopride Succinate [mart.]
35. Ccg-269590
36. Cs-3907
37. Ks-1283
38. Prucalopride Succinate [who-dd]
39. 4-amino-5-chloro-n-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide,butanedioic Acid
40. Ac-29960
41. Butanedioic Acid 4-amino-5-chloro-2,3-dihydro-n-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarb
42. Hy-12694
43. Smr004702981
44. Db-065276
45. Prucalopride Succinate [orange Book]
46. Ft-0745512
47. Sw219198-1
48. D10152
49. A812449
50. J-519956
51. Q27260539
52. B0084-470898
| Molecular Weight | 486.0 g/mol |
|---|---|
| Molecular Formula | C22H32ClN3O7 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 9 |
| Exact Mass | 485.1928781 g/mol |
| Monoisotopic Mass | 485.1928781 g/mol |
| Topological Polar Surface Area | 151 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 538 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.
Laxatives
Agents that produce a soft formed stool, and relax and loosen the bowels, typically used over a protracted period, to relieve CONSTIPATION. (See all compounds classified as Laxatives.)
Serotonin 5-HT4 Receptor Agonists
Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT4 RECEPTORS. (See all compounds classified as Serotonin 5-HT4 Receptor Agonists.)
A06AX05
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2019-11-13
Registration Number : Su331-18-ND
Manufacturer Name : Alven Laboratories sro
Manufacturer Address : Holická 1173/49a, Hodolany, 779 00 Olomouc, Czech Republic
| Available Reg Filing : ASMF |
Registrant Name : Menarini Korea Co., Ltd.
Registration Date : 2025-01-17
Registration Number : Su11-3-ND
Manufacturer Name : PharmaZell GmbH
Manufacturer Address : Rosenheimer Straße 43 83064 Raubling Germany
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-13
Pay. Date : 2023-09-28
DMF Number : 37576
Submission : 2022-10-31
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-10-06
Pay. Date : 2022-09-19
DMF Number : 34970
Submission : 2020-08-21
Status : Active
Type : II
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm :
NDC Package Code : 42765-011
Start Marketing Date : 2020-06-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (2kg/2kg)
Marketing Category : BULK INGREDIENT
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-04-04
Pay. Date : 2023-04-17
DMF Number : 36765
Submission : 2022-02-18
Status : Active
Type : II
Date of Issue : 2024-02-20
Valid Till : 2026-12-06
Written Confirmation Number : WC-0416
Address of the Firm :
NDC Package Code : 58159-083
Start Marketing Date : 2021-06-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT
Deccan Nutraceuticals: A global leader in the integrated development, manufacturing, and marketing of pharmaceutical products.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-06-14
Pay. Date : 2023-06-06
DMF Number : 38084
Submission : 2023-06-04
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-13
Pay. Date : 2023-09-28
DMF Number : 37576
Submission : 2022-10-31
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : Complete
Rev. Date : 2022-10-06
Pay. Date : 2022-09-19
DMF Number : 34970
Submission : 2020-08-21
Status : Active
Type : II
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Complete
Rev. Date : 2023-04-04
Pay. Date : 2023-04-17
DMF Number : 36765
Submission : 2022-02-18
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-10-24
Pay. Date : 2023-08-11
DMF Number : 37911
Submission : 2023-08-17
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11649
Submission : 1995-09-12
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12826
Submission : 1998-01-20
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2022-08-03
Pay. Date : 2022-06-13
DMF Number : 37181
Submission : 2022-06-13
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2022-10-19
Pay. Date : 2022-09-09
DMF Number : 37301
Submission : 2022-08-30
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2020-10-14
Pay. Date : 2020-08-13
DMF Number : 35038
Submission : 2020-08-28
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2023-10-12
Pay. Date : 2023-07-26
DMF Number : 34862
Submission : 2020-09-25
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm : Unit-IV, Plot No: 34B, 40B & 60B, J.N. Pharma City, Thanam (V), Parawada (M), An...
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
Date of Issue : 2024-02-20
Valid Till : 2026-12-06
Written Confirmation Number : WC-0416
Address of the Firm : Plot No. 111, SIDCO Industrial Estate, Kakkalur, Thiruvallur 602 003, Tamil Nadu...
Date of Issue : 2024-03-01
Valid Till : 2027-02-28
Written Confirmation Number : WC-0474
Address of the Firm : Village Bhondsi, Tehsil Sohna, District Gurgaon -122102, Haryana, India

Date of Issue : 2025-09-19
Valid Till : 2028-05-05
Written Confirmation Number : WC-0349
Address of the Firm : Unit-II, Sy. Nos. 50, 53, 53/A, 54 & 54/A,Kardanur (Village), Patancheru (Mandal...

Date of Issue : 2025-11-11
Valid Till : 2028-07-02
Written Confirmation Number : WC-0147
Address of the Firm : 100% EOU, Plot No.33, 33A, 40 to 47,Block C, D, E, H, I& AM,Raichur Industrial G...

Date of Issue : 2025-08-19
Valid Till : 2028-08-08
Written Confirmation Number : WC-0382
Address of the Firm : Survey No. 353, Domadugu (V),Gummadidala (M), Sangareddy District,Pincode-502001...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2019-11-13
Registration Number : Su331-18-ND
Manufacturer Name : Alven Laboratories sro
Manufacturer Address : Holická 1173/49a, Hodolany, 779 00 Olomouc, Czech Republic
Registrant Name : Menarini Korea Co., Ltd.
Registration Date : 2025-01-17
Registration Number : Su11-3-ND
Manufacturer Name : PharmaZell GmbH
Manufacturer Address : Rosenheimer Straße 43 83064 Raubling Germany
Registrant Name : Menarini Korea Co., Ltd.
Registration Date : 2012-10-26
Registration Number : Su217-15-ND
Manufacturer Name : Janssen Pharmaceutica NV
Manufacturer Address : Janssen Pharmaceuticalaan 3 B-2440 Geel Belgium

Registrant Name : Eltek Pharmachem Co., Ltd.
Registration Date : 2019-05-28
Registration Number : Su469-1-ND
Manufacturer Name : Shilpa Pharma Lifesciences L...
Manufacturer Address : Raichur Industrial Growth Centre, Plot Nos. 33, 33A, 40 to 47, Block C,D,E,H,I & AM, ...

Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2018-06-25
Registration Number : Su258-8-ND
Manufacturer Name : Symed Labs Ltd (Unit-Ⅰ)
Manufacturer Address : Survey No.353, 35 4& 467 Domadugu Village, Gummadidala Mandal, SangaReddy District - ...

Registrant Name : Agerson Bio Co., Ltd.
Registration Date : 2024-09-04
Registration Number : 6160-5-ND
Manufacturer Name : Agerson Bio Co., Ltd.
Manufacturer Address : 7 Geumwang Techno 5-gil, Geumwang-eup, Eumseong-gun, Chungcheongbuk-do

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
NDC Package Code : 42765-011
Start Marketing Date : 2020-06-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (2kg/2kg)
Marketing Category : BULK INGREDIENT
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
NDC Package Code : 58159-083
Start Marketing Date : 2021-06-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 84386-029
Start Marketing Date : 2025-01-22
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 54893-0123
Start Marketing Date : 2022-08-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 82920-042
Start Marketing Date : 2022-10-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 66022-0207
Start Marketing Date : 2018-12-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 16436-0129
Start Marketing Date : 2022-05-27
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (75kg/75kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 73435-030
Start Marketing Date : 2022-12-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Alven Laboratories is a pharmaceutical company focused on the development, scale-up, and production of original and generic Active Pharmaceutical Ingredients (APIs). With expertise...
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for pharmaceutical and biotech industries. LGM also operates as a full-service CDMO, offering formulat...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
About the Company : Nuray Chemicals Pvt Ltd, established in 2012 near Chennai, is an API manufacturer for highly regulated markets. Its state-of-the-art R&D facility specializes in synthesizing NCEs, ...
Deccan Nutraceuticals: A global leader in the integrated development, manufacturing, and marketing of pharmaceutical products.
About the Company : Deccan Nutraceuticals Pvt. Ltd. (DNPL) is a group company of Alkaloids Corporation (India), was founded in 2001 and operates from a 22,000 sq. m. facility in Pune (India). Their co...
About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...
About the Company : Established in May 2012, Shandong Loncom Pharmaceutical is a wholly owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Located in the Qihe Economic Development Zone, Sh...
About the Company : Aspire group was established in the year 2000 with a motto of quality drug for better health of all. In its journey till date, aspire has developed enormous reputation, consistent ...

About the Company : Centaur accepts change as a constant, and continuously innovates to remain significant. Centaur has built knowledge sharing relationships with the pharmaceutical majors in areas of...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Prucalopride is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Lead Product(s): Prucalopride Succinate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Motegrity-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 09, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Prucalopride Succinate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus receives final approval from USFDA for Prucalopride Tablets
Details : Prucalopride is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Product Name : Motegrity-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Motegrity-Generic (Prucalopride Succinate) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Lead Product(s): Prucalopride Succinate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Motegrity-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 26, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Prucalopride Succinate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches Prucalopride Tablets in the US market Post FDA Approval
Details : Motegrity-Generic (Prucalopride Succinate) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Product Name : Motegrity-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2025

Details:
Nora Pharma has acquired the rights to two gastrointestinal drugs, which includes Motegrity-Generic (prucalopride succinate). It is indicated for the treatment of chronic idiopathic constipation.
Lead Product(s): Prucalopride Succinate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Motegrity-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Nora Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 10, 2025

Lead Product(s) : Prucalopride Succinate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Nora Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Sunshine Biopharma to Launch Two GI Drugs in $200M Canadian Market
Details : Nora Pharma has acquired the rights to two gastrointestinal drugs, which includes Motegrity-Generic (prucalopride succinate). It is indicated for the treatment of chronic idiopathic constipation.
Product Name : Motegrity-Generic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 10, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Prucalopride is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Lead Product(s): Prucalopride Succinate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Motegrity
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 02, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Prucalopride Succinate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ANI Pharmaceuticals Announces FDA Approval of Prucalopride with CGT Exclusivity
Details : Prucalopride is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Product Name : Motegrity
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 02, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Prucalopride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.
Lead Product(s): Prucalopride Succinate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Takeda Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 18, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Prucalopride Succinate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Prucalopride For Functional Constipation in Children and Teenagers
Details : Prucalopride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Prucalopride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Constipation.
Lead Product(s): Prucalopride Succinate,Macrogol,Lactulose
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Prucalopride Succinate,Macrogol,Lactulose
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Prucalopride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2014

Details:
Prucalopride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Gastroparesis.
Lead Product(s): Prucalopride Succinate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Johnson & Johnson Innovative Medicine
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 09, 2014

Lead Product(s) : Prucalopride Succinate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Prucalopride Versus Placebo in Gastroparesis
Details : Prucalopride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Gastroparesis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 09, 2014

Details:
Prucalopride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Lead Product(s): Prucalopride Succinate,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Hotel Dieu Hospital | Johnson & Johnson Innovative Medicine
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 30, 2013

Lead Product(s) : Prucalopride Succinate,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Hotel Dieu Hospital | Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule
Details : Prucalopride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 30, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Prucalopride Succinate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Prucalopride Succinate,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 08, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Prucalopride Succinate,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Prucalopride Succinate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 08, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Prucalopride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Constipation.
Lead Product(s): Prucalopride Succinate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 16, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Prucalopride Succinate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity
Details : Prucalopride is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Constipation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 16, 2012

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : PRUCALOPRIDE SUCCINATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 1MG BASE
Approval Date : 2025-06-24
Application Number : 218795
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : PRUCALOPRIDE SUCCINATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2MG BASE
Approval Date : 2025-06-24
Application Number : 218795
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Brand Name : PRUCALOPRIDE SUCCINATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2MG BASE
Approval Date : 2025-06-24
Application Number : 218295
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : PRUCALOPRIDE SUCCINATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2MG BASE
Approval Date : 2025-06-24
Application Number : 219160
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : PRUCALOPRIDE SUCCINATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2MG BASE
Approval Date : 2025-06-24
Application Number : 218963
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : PRUCALOPRIDE SUCCINATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 1MG BASE
Approval Date : 2025-06-24
Application Number : 219193
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : PRUCALOPRIDE SUCCINATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2MG BASE
Approval Date : 2025-06-24
Application Number : 219193
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : PRUCALOPRIDE SUCCINATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 1MG BASE
Approval Date : 2024-12-26
Application Number : 218492
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : PRUCALOPRIDE SUCCINATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 2MG BASE
Approval Date : 2024-12-26
Application Number : 218492
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Brand Name : MOTEGRITY
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 1MG BASE
Approval Date : 2018-12-14
Application Number : 210166
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : India
Brand Name : C2WIN
Dosage Form : Tablet
Dosage Strength : 1MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 1MG
Brand Name : C2WIN
Approval Date :
Application Number :
Registration Country : India

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : South Korea
Brand Name : Prusolo Tablet
Dosage Form : Tablet
Dosage Strength : 1MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : South Korea

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 1MG
Brand Name : Prusolo Tablet
Approval Date :
Application Number :
Registration Country : South Korea

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : South Korea
Brand Name : Prusolo Tablet
Dosage Form : Tablet
Dosage Strength : 2MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : South Korea

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 2MG
Brand Name : Prusolo Tablet
Approval Date :
Application Number :
Registration Country : South Korea

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Argentina
Brand Name : Resolide
Dosage Form : Coated Tablet
Dosage Strength : 1MG
Packaging : 28 Tabs
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Argentina

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging : 28 Tabs
Regulatory Info :
Dosage : Coated Tablet
Dosage Strength : 1MG
Brand Name : Resolide
Approval Date :
Application Number :
Registration Country : Argentina

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Argentina
Brand Name : Resolide
Dosage Form : Coated Tablet
Dosage Strength : 2MG
Packaging : 28 Tabs
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Argentina

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging : 28 Tabs
Regulatory Info :
Dosage : Coated Tablet
Dosage Strength : 2MG
Brand Name : Resolide
Approval Date :
Application Number :
Registration Country : Argentina

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Russia
Brand Name : Vegaprat
Dosage Form : Tablet
Dosage Strength : 1MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Russia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 1MG
Brand Name : Vegaprat
Approval Date :
Application Number :
Registration Country : Russia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Russia
Brand Name : Vegaprat
Dosage Form : Tablet
Dosage Strength : 2MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Russia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 2MG
Brand Name : Vegaprat
Approval Date :
Application Number :
Registration Country : Russia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Saudi Arabia
Brand Name : Constipru
Dosage Form : Coated Tablet
Dosage Strength : 1MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Saudi Arabia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Coated Tablet
Dosage Strength : 1MG
Brand Name : Constipru
Approval Date :
Application Number :
Registration Country : Saudi Arabia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Saudi Arabia
Brand Name : Constipru
Dosage Form : Coated Tablet
Dosage Strength : 2MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Saudi Arabia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Coated Tablet
Dosage Strength : 2MG
Brand Name : Constipru
Approval Date :
Application Number :
Registration Country : Saudi Arabia

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : M-14
Exclusivity Expiration Date : 2028-07-10
Application Number : 210166
Product Number : 1
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : M-14
Exclusivity Expiration Date : 2028-07-10
Application Number : 210166
Product Number : 2
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : CGT
Exclusivity Expiration Date : 2025-06-24
Application Number : 218492
Product Number : 1
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : CGT
Exclusivity Expiration Date : 2025-06-24
Application Number : 218492
Product Number : 2
Exclusivity Details :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Patent Expiration Date : 2015-11-16
Date Granted : 2006-05-09
Brand Name : RESOTRAN
Patent Number : 2205573
Filing Date : 1995-11-16
Strength per Unit : 1 mg
Dosage Form : Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2015-11-16
Date Granted : 2006-05-09

Patent Expiration Date : 2015-11-16
Date Granted : 2006-05-09
Brand Name : RESOTRAN
Patent Number : 2205573
Filing Date : 1995-11-16
Strength per Unit : 2 mg
Dosage Form : Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2015-11-16
Date Granted : 2006-05-09

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
68
PharmaCompass offers a list of Prucalopride Succinate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Prucalopride Succinate manufacturer or Prucalopride Succinate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Prucalopride Succinate manufacturer or Prucalopride Succinate supplier.
PharmaCompass also assists you with knowing the Prucalopride Succinate API Price utilized in the formulation of products. Prucalopride Succinate API Price is not always fixed or binding as the Prucalopride Succinate Price is obtained through a variety of data sources. The Prucalopride Succinate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 179474-85-2 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 179474-85-2, including repackagers and relabelers. The FDA regulates 179474-85-2 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 179474-85-2 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 179474-85-2 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 179474-85-2 supplier is an individual or a company that provides 179474-85-2 active pharmaceutical ingredient (API) or 179474-85-2 finished formulations upon request. The 179474-85-2 suppliers may include 179474-85-2 API manufacturers, exporters, distributors and traders.
click here to find a list of 179474-85-2 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A 179474-85-2 DMF (Drug Master File) is a document detailing the whole manufacturing process of 179474-85-2 active pharmaceutical ingredient (API) in detail. Different forms of 179474-85-2 DMFs exist exist since differing nations have different regulations, such as 179474-85-2 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 179474-85-2 DMF submitted to regulatory agencies in the US is known as a USDMF. 179474-85-2 USDMF includes data on 179474-85-2's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 179474-85-2 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 179474-85-2 suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a 179474-85-2 Drug Master File in Korea (179474-85-2 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 179474-85-2. The MFDS reviews the 179474-85-2 KDMF as part of the drug registration process and uses the information provided in the 179474-85-2 KDMF to evaluate the safety and efficacy of the drug.
After submitting a 179474-85-2 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 179474-85-2 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of 179474-85-2 suppliers with KDMF on PharmaCompass.
A 179474-85-2 written confirmation (179474-85-2 WC) is an official document issued by a regulatory agency to a 179474-85-2 manufacturer, verifying that the manufacturing facility of a 179474-85-2 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 179474-85-2 APIs or 179474-85-2 finished pharmaceutical products to another nation, regulatory agencies frequently require a 179474-85-2 WC (written confirmation) as part of the regulatory process.
click here to find a list of 179474-85-2 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 179474-85-2 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 179474-85-2 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 179474-85-2 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 179474-85-2 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 179474-85-2 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 179474-85-2 suppliers with NDC on PharmaCompass.
179474-85-2 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 179474-85-2 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 179474-85-2 GMP manufacturer or 179474-85-2 GMP API supplier for your needs.
A 179474-85-2 CoA (Certificate of Analysis) is a formal document that attests to 179474-85-2's compliance with 179474-85-2 specifications and serves as a tool for batch-level quality control.
179474-85-2 CoA mostly includes findings from lab analyses of a specific batch. For each 179474-85-2 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
179474-85-2 may be tested according to a variety of international standards, such as European Pharmacopoeia (179474-85-2 EP), 179474-85-2 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (179474-85-2 USP).